{
    "clinical_study": {
        "@rank": "88913", 
        "acronym": "SPRESAS", 
        "arm_group": [
            {
                "arm_group_label": "erythropoiesis-stimulating agents", 
                "description": "Patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1), treated with erythropoiesis-stimulating agents."
            }, 
            {
                "arm_group_label": "Transfusion support", 
                "description": "A control group of patients who received only transfusional support."
            }
        ], 
        "brief_summary": {
            "textblock": "Reviewing Spanish record of myelodysplastic syndromes (RESMD) data base in the group of\n      patients with MDS. The information will be collected retrospectively from diagnosis of MDS,\n      until the date of December 31, 2011."
        }, 
        "brief_title": "Spanish Registry of Erythropoietic Stimulating Agents Study", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Review of RESMD data base in the group of patients with MDS from diagnosis of low risk\n      myelodysplastic syndrome (MDS) and occurrence of anemia that began treatment with\n      erythropoiesis stimulating agent (ESAs) / support transfusional before December 31, 2011. In\n      all cases, data obtained will be prior to the date of the start of the study to ensure its\n      retrospective nature, thus reflecting the routine use of erythropoietic agents in clinical\n      and non-interference in the doctor's clinical practice."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient has given consent to the collection of data in the RESMD.\n\n          -  Age \u2265 18 years.\n\n          -  Patient must be diagnosed with MDS according to WHO classifications or FAB low-risk\n             (IPSS low and intermediate-1) with anemia (Hb \u2264 11 g / dL).\n\n          -  The patient has studies at the time of diagnosis discard the possibility that MDS\n             anemia is due to deficiency of factors (iron, vitamin B12 or folic acid).\n\n          -  Initiation of treatment with ESAs or support transfusional at any spanish hematology\n             service before December 31, 2011.\n\n        Exclusion Criteria:\n\n          -  Pretreatment of SMD with hypomethylating agents, lenalidomide, chemotherapy, other."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with MDS according to WHO classifications or FAB low-risk (IPSS low and\n        intermediate-1) with anemia (Hb \u2264 11 g / dL) and treatment (support / ESA) started before\n        December 31, 2011."
            }
        }, 
        "enrollment": {
            "#text": "900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739452", 
            "org_study_id": "GESMD-SPRESAS-2012-01"
        }, 
        "intervention_browse": {
            "mesh_term": "Hematinics"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Low-risk MDS", 
            "myelodysplastic syndrome", 
            "retrospective"
        ], 
        "lastchanged_date": "November 29, 2012", 
        "number_of_groups": "2", 
        "official_title": "National Registry of Patients Diagnosed With Low-risk Myelodysplastic Syndromes According to the Criteria of the WHO / French-American-British Classification System (FAB) and IPSS and Treated With Erythropoietic Agents.", 
        "overall_contact": {
            "email": "secretaria@gesmd.org", 
            "last_name": "Guillermo Sanz, MD", 
            "phone": "+34 93 434 44 12"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Universitario de Salamanca", 
                "last_name": "Maria Consuelo Ca\u00f1izo, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hospital Universitario de Salamanca", 
                "last_name": "Mar\u00eda D\u00edez, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Collect and evaluate retrospectively the Spanish experience of anemia treatment in patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1) evaluating the efficacy and safety of treatment with ESAs received for at least 24 weeks and the evolution of a control group of patients who received only transfusional support.", 
            "measure": "Collect and evaluate the Spanish experience of anemia treatment.", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739452"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "In responders at week 24 of treatment, determine the duration of response after 48 weeks of treatment.", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Evaluate overall survival in the two groups of patients, support transfusional versus ESA.", 
                "measure": "Overall survival.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Security: To determine the frequency, type, intensity and severity of adverse events and their possible relationship with the various ESA and progression to acute myelogenous leukemia.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}